New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
16:02 EDTMNKDMannKind reports Q4 EPS (23c) , consensus (18c)
News For MNKD From The Last 14 Days
Check below for free stories on MNKD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent MNKD news | >>
April 11, 2014
06:04 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Subscribe for More Information
April 10, 2014
12:29 EDTMNKDMannKind retreats after potential rival starts IPO process
Shares of drug maker MannKind (MNKD) are falling after a potential competitor, Dance Biopharm, sought to launch an initial public offering. WHAT'S NEW: Dance Biopharm filed papers with the SEC to raise $75M through an IPO last night. Like Mannkind, Dance has developed an inhaled insulin product that is supposed to treat diabetes. Dance's lead product, Dance 501, is designed to deliver liquid insulin through a small, handheld electronic inhaler, Dance stated in its IPO application. The company plans to launch a Phase III trial of the product in early 2015 and eventually seek regulatory approval of the product in the EU, U.S., and China. MannKind's AFREZZA, which is designed to deliver insulin through an inhaler, is currently under review for approval by the FDA. PRICE ACTION: In early afternoon trading, MannKind sank 30c, or 4.3%, to $6.70.
11:03 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX
April 9, 2014
16:00 EDTMNKDOptions Update; April 9, 2014
Subscribe for More Information
15:41 EDTMNKDMannKind volatility decreases to 90
Subscribe for More Information
10:23 EDTMNKDOptions with decreasing implied volatility: MNKD QCOR MU KMX
Subscribe for More Information
05:56 EDTMNKDStocks with implied volatility below IV index mean; QCOR MNKD
Stocks with implied volatility below IV index mean; Questcor (QCOR) 47, MannKind (MNKD) 83 according to iVolatility.
April 8, 2014
11:03 EDTMNKDPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
10:03 EDTMNKDOn The Fly: Analyst Initiation Summary
1st United Bancorp (FUBC) initiated with a Neutral at Macquarie... Avista (AVA) initiated with a Fair Value at CRT Capital... Castlight Health (CSLT) initiated with a Neutral at Goldman... Cempra (CEMP) initiated with an Equalweight at Barclays... Coca-Cola (KO) initiated with a Buy at BTIG... JinkoSolar (JKS) initiated with an Overweight at Barclays... Lumenis (LMNS) initiated with a Buy at Goldman... National Retail Properties (NNN) initiated with an Overweight at Morgan Stanley... PepsiCo (PEP) initiated with a Buy at BTIG... Realty Income (O) initiated with an Underweight at Morgan Stanley... Teekay (TK) initiated with an Outperform at Raymond James... Twitter (TWTR) initiated with a Buy at Janney Capital... Realogy (RLGY) initiated with an Outperform at RBC Capital... Bristow Group (BRS) initiated with an Outperform at Clarkson Capital... Era Group (ERA) initiated with an Outperform at Clarkson Capital... Endurance (EIGI) initiated with a Buy at Craig-Hallum... Tutor Perini (TPC) initiated with an Overweight at Stephens... MannKind (MNKD) initiated with an Outperform at Brinson Patrick... TriCo Bancshares (TCBK) initiated with an Outperform at Fig Partners... Achaogen (AKAO) initiated with an Outperform at Cowen.
08:25 EDTMNKDMannKind initiated with an Outperform at Brinson Patrick
Subscribe for More Information
06:27 EDTMNKDStocks with implied volatility below IV index mean; DLLR MNKD
Subscribe for More Information
April 7, 2014
16:30 EDTMNKDFDA extension of MannKind's Afrezza PDUFA not a surprise, Barron's says
The FDA's decision to extend the Prescription Drug User Fee Act, or PDUFA, for Mankind's Afrezza was not a surprise because of all the information and feedback that the FDA has to incorporate into its approval decision, Barron's reports in its "Stocks to Watch" blog, citing Cowen’s Simos Simeonidis and Yatin Suneja. Reference Link
16:01 EDTMNKDOptions Update; April 7, 2014
Subscribe for More Information
12:00 EDTMNKDMannKind falls 11.8%
Subscribe for More Information
11:15 EDTMNKD Options with decreasing implied volatility: MNKD GALT DLLR APOL
Subscribe for More Information
10:00 EDTMNKDMannKind falls 11.2%
Subscribe for More Information
09:34 EDTMNKDActive equity options trading on open
Subscribe for More Information
09:10 EDTMNKDOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTMNKDMannKind falls 12.4%
MannKind is down 12.4%, or 85c, to $6.02
05:51 EDTMNKDMannKind announces FDA extension of PDUFA date for Afrezza
Subscribe for More Information
1 | 2 | all recent MNKD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use